Clinical insights and strategies for adding Ortho-K services to your practice.
May 1, 2020 By Laura Kirkeby, CO The use of atropine has been known to slow the progression of myopia for many...
AL measurement has not traditionally been considered part of mainstream optometry.
There are two strategies to consider for stopping atropine treatment.
Individual interventions may not result in the expected efficacy.
Results of a recent study on combining orthokeratology and topical atropine 0.01%.
Results of a single masked, randomized two-year controlled clinical trial
The real value of this study, however, lies in the follow-up findings after cessation of the outdoor intervention.
Practitioners offering myopia management need to know the effect a patient’s binocular vision status has on their management strategies.
Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
Combined interventions for myopia will potentially influence the standard of care.
Existing evidence has failed to convince doctors to uniformly embrace treatments for myopic progression control.
Axial elongation rate is faster in younger children undergoing ortho-k treatment.
There is a strong correlation between the amount of myopia and the length of the eye in all individuals.
When should one start atropine treatment for myopes?
Dwight Akerman, OD, MBA, FAAO, FBCLA Professor Ian Flitcroft wrote, “… there is no evidence of a safe threshold level of myopia...
By Karen Lahav-Yacouel PhD Student – Brien Holden Vision Institute Myopia is on the rise globally. Research on ways to minimise the...